Tomonori Nakazato

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Coexistence of Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Transthyretin Amyloidosis in an Elderly Japanese Patient With Splenic Marginal Zone Lymphoma: An Autopsy Case Report.

Coexistence of Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Transthyretin Amyloidosis in an Elderly Japanese Patient With Splenic Marginal Zone Lymphoma: An Autopsy Case Report.

Journal: Cureus

Published: May 17, 2026

Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.

Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.

Journal: British journal of haematology

Published: February 21, 2026

Evolution of carbapenem-resistant Klebsiella pneumoniae after ceftolozane-tazobactam exposure in a patient after cord blood transplantation: A case report.

Evolution of carbapenem-resistant Klebsiella pneumoniae after ceftolozane-tazobactam exposure in a patient after cord blood transplantation: A case report.

Journal: Journal of global antimicrobial resistance

Published: October 06, 2025

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Journal: International journal of hematology

Published: September 03, 2025

Complex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.

Complex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.

Journal: The American journal of case reports

Published: August 11, 2025

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Journal: International journal of hematology

Published: July 14, 2025

Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.

Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.

Journal: International journal of hematology

Published: June 06, 2025

Fatal Eosinophilia-Associated Thrombotic Microangiopathy and the Role of Renal Charcot-Leyden Crystals.

Fatal Eosinophilia-Associated Thrombotic Microangiopathy and the Role of Renal Charcot-Leyden Crystals.

Journal: Kidney international reports

Published: March 30, 2025

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Journal: Cardio-oncology (London, England)

Published: February 13, 2025

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

Journal: Cancer science

Published: September 27, 2024

Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL.

Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL.

Journal: International journal of hematology

Published: August 23, 2024

Unprecedented Megakaryocytic Blast Phase Transformation in Chronic Myeloid Leukemia After 16 Years of Tyrosine Kinase Inhibitor Therapy.

Unprecedented Megakaryocytic Blast Phase Transformation in Chronic Myeloid Leukemia After 16 Years of Tyrosine Kinase Inhibitor Therapy.

Journal: Cureus

Published: August 21, 2024

Showing 1-12 of 89

Last Updated: 09/26/2026